To characterize the interaction of the HER-2 and TGF-β pathways in this context, the effects of HER-2 overexpression on the TGF-β response in the mesenchymal-like breast cancer cell line MDA-MB-231 were examined. Here, ERBB2 is linked to breast carcinoma.